Sanofi Beats Estimates Ahead of CEO Transition

SANOFI reported first-quarter earnings on Thursday that exceeded market expectations, driven by robust demand for its flagship asthma and eczema treatment, Dupixent. The results provide a stable foundation for incoming CEO Belén Garijo, a former executive at the firm who previously led Germany based MERCK KGAA. Garijo is scheduled to take the helm by the end of the month following the abrupt departure of former CEO Paul Hudson in February.